Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
Aridis Receives FDA Feedback on Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design May 31, 2023
Remark AI Awarded $6 million Rio De Janeiro police contract May 31, 2023
Adamas One Acquires Minority Equity Stake in NexGenAI Solutions Group May 31, 2023
LL Flooring Receives Unsolicited Buyout Offer May 31, 2023
Marker Therapeutics Reports Positive MT-601 Pre-Clinical Data May 31, 2023
Next
Prev

24/7 MN – (NASDAQ: GLSI) GREENWICH LIFESCIENCES INC. shares are up 10% on light volume in pre-market trading. The company announced they can proceed with phase 3 trials. The stock is $9.37 a share and has more than 1777 trades this summer morning.

  • Jul 12, 2022 at 7:50 AM

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

https://www.businesswire.com/news/home/20220712005542/en/Greenwich-LifeSciences-Announces-Removal-of-Clinical-Hold-Permitting-Phase-III-Clinical-Trial-to-Proceed

RelatedNews

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.